Cargando…

Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study

Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory airway disease punctuated by exacerbations (AECOPD). Subjects with frequent AECOPD, defined by having at least two exacerbations per year, experience accelerated loss of lung function, deterioration in quality of life and increas...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulati, Swati, Wells, J. Michael, Urdaneta, Gisel P., Balestrini, Kira, Vital, Isabel, Tovar, Katherine, Barnes, Jarrod W., Bhatt, Surya P., Campos, Michael, Krick, Stefanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539353/
https://www.ncbi.nlm.nih.gov/pubmed/31075857
http://dx.doi.org/10.3390/ijms20092292
_version_ 1783422367729451008
author Gulati, Swati
Wells, J. Michael
Urdaneta, Gisel P.
Balestrini, Kira
Vital, Isabel
Tovar, Katherine
Barnes, Jarrod W.
Bhatt, Surya P.
Campos, Michael
Krick, Stefanie
author_facet Gulati, Swati
Wells, J. Michael
Urdaneta, Gisel P.
Balestrini, Kira
Vital, Isabel
Tovar, Katherine
Barnes, Jarrod W.
Bhatt, Surya P.
Campos, Michael
Krick, Stefanie
author_sort Gulati, Swati
collection PubMed
description Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory airway disease punctuated by exacerbations (AECOPD). Subjects with frequent AECOPD, defined by having at least two exacerbations per year, experience accelerated loss of lung function, deterioration in quality of life and increase in mortality. Fibroblast growth factor (FGF)23, a hormone associated with systemic inflammation and altered metabolism is elevated in COPD. However, associations between FGF23 and AECOPD are unknown. In this cross-sectional study, individuals with COPD were enrolled between June 2016 and December 2016. Plasma samples were analyzed for intact FGF23 levels. Logistic regression analyses were used to measure associations between clinical variables, FGF23, and the frequent exacerbator phenotype. Our results showed that FGF23 levels were higher in frequent exacerbators as compared to patients without frequent exacerbations. FGF23 was also independently associated with frequent exacerbations (OR 1.02; 95%CI 1.004–1.04; p = 0.017), after adjusting for age, lung function, smoking, and oxygen use. In summary, FGF23 was associated with the frequent exacerbator phenotype and correlated with number of exacerbations recorded retrospectively and prospectively. Further studies are needed to explore the role of FGF 23 as a possible biomarker for AECOPD to better understand the pathobiology of COPD and to help develop therapeutic targets.
format Online
Article
Text
id pubmed-6539353
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65393532019-06-04 Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study Gulati, Swati Wells, J. Michael Urdaneta, Gisel P. Balestrini, Kira Vital, Isabel Tovar, Katherine Barnes, Jarrod W. Bhatt, Surya P. Campos, Michael Krick, Stefanie Int J Mol Sci Article Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory airway disease punctuated by exacerbations (AECOPD). Subjects with frequent AECOPD, defined by having at least two exacerbations per year, experience accelerated loss of lung function, deterioration in quality of life and increase in mortality. Fibroblast growth factor (FGF)23, a hormone associated with systemic inflammation and altered metabolism is elevated in COPD. However, associations between FGF23 and AECOPD are unknown. In this cross-sectional study, individuals with COPD were enrolled between June 2016 and December 2016. Plasma samples were analyzed for intact FGF23 levels. Logistic regression analyses were used to measure associations between clinical variables, FGF23, and the frequent exacerbator phenotype. Our results showed that FGF23 levels were higher in frequent exacerbators as compared to patients without frequent exacerbations. FGF23 was also independently associated with frequent exacerbations (OR 1.02; 95%CI 1.004–1.04; p = 0.017), after adjusting for age, lung function, smoking, and oxygen use. In summary, FGF23 was associated with the frequent exacerbator phenotype and correlated with number of exacerbations recorded retrospectively and prospectively. Further studies are needed to explore the role of FGF 23 as a possible biomarker for AECOPD to better understand the pathobiology of COPD and to help develop therapeutic targets. MDPI 2019-05-09 /pmc/articles/PMC6539353/ /pubmed/31075857 http://dx.doi.org/10.3390/ijms20092292 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gulati, Swati
Wells, J. Michael
Urdaneta, Gisel P.
Balestrini, Kira
Vital, Isabel
Tovar, Katherine
Barnes, Jarrod W.
Bhatt, Surya P.
Campos, Michael
Krick, Stefanie
Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study
title Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study
title_full Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study
title_fullStr Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study
title_full_unstemmed Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study
title_short Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study
title_sort fibroblast growth factor 23 is associated with a frequent exacerbator phenotype in copd: a cross-sectional pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539353/
https://www.ncbi.nlm.nih.gov/pubmed/31075857
http://dx.doi.org/10.3390/ijms20092292
work_keys_str_mv AT gulatiswati fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy
AT wellsjmichael fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy
AT urdanetagiselp fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy
AT balestrinikira fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy
AT vitalisabel fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy
AT tovarkatherine fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy
AT barnesjarrodw fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy
AT bhattsuryap fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy
AT camposmichael fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy
AT krickstefanie fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy